Format

Send to

Choose Destination
Future Oncol. 2017 Dec;13(28):2537-2546. doi: 10.2217/fon-2017-0307. Epub 2017 Sep 20.

A review of bevacizumab in the treatment of malignant pleural mesothelioma.

Author information

1
Department of Thoracic Oncology & CIC 1425/CLIP2 Paris-Nord, Bichat-Claude Bernard Hospital, APHP, Paris, France.
2
University Paris-Diderot, Paris, France.
3
Pharmacy Department, Bichat-Claude Bernard Hospital, APHP, Paris, 46, rue Henri Huchard, 75877 Paris Cedex 18, France.

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF plays a key mitogen for MPM cells physiopathology. Bevacizumab, a monoclonal anti-VEGF antibody, was a rational approach to be tested in MPM. Based on the results of the Phase III IFCT-0701 mesothelioma avastin cisplatin pemetrexed study, cisplatin-pemetrexed-bevacizumab is now the accepted standard in France. The National Comprehensive Cancer Network guidelines have also included this combination as an option for standard front-line therapy. This review summarized the efficacy and safety data of bevacizumab in the treatment of patients with MPM.

KEYWORDS:

angiogenesis inhibitor; bevacizumab; malignant pleural mesothelioma

PMID:
29086616
DOI:
10.2217/fon-2017-0307
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center